These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 28903995)

  • 21. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
    Chin LP; Soo RA; Soong R; Ou SH
    J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
    J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L; Zhang H; Shao W; Chen B
    Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.
    Liu S; Yang H; Jiang Y; Zhang T; Yan R; Zhang J
    Future Med Chem; 2018 Jul; 10(14):1705-1720. PubMed ID: 29961337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
    Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
    Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
    Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
    Zhu VW; Upadhyay D; Schrock AB; Gowen K; Ali SM; Ou SH
    Lung Cancer; 2016 Jul; 97():48-50. PubMed ID: 27237027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
    Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance.
    Zhong E; Huang H
    BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27797842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
    Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
    Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Guisier F; Piton N; Salaun M; Thiberville L
    Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437
    [No Abstract]   [Full Text] [Related]  

  • 34. First macrocyclic 3
    Basit S; Ashraf Z; Lee K; Latif M
    Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of ROS1 rearrangements in non-small cell lung cancer].
    Xu L; Zhao R; Dong Z; Zhu T
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):663-70. PubMed ID: 24345493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Arnaoutakis K
    N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
    [No Abstract]   [Full Text] [Related]  

  • 37. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Solomon BJ
    N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
    Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
    Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion.
    Li H; Pan Y; Wang R; Li Y; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):185-7. PubMed ID: 25230898
    [No Abstract]   [Full Text] [Related]  

  • 40. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
    Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
    Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.